32097
依托考昔
VETRANAL®, analytical standard
别名:
5-氯-3-[4-(甲磺酰基)苯基]-2-(2-甲基-5-吡啶基)吡啶, 5-氯-6′-甲基-3-[4-(甲磺酰基)苯基]]-2,3′-联吡啶
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C18H15ClN2O2S
化学文摘社编号:
分子量:
358.84
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
8073797
产品名称
依托考昔, VETRANAL®, analytical standard
InChI
1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3
SMILES string
CC1=NC=C(C2=C(C3=CC=C(S(C)(=O)=O)C=C3)C=C(Cl)C=N2)C=C1
InChI key
MNJVRJDLRVPLFE-UHFFFAOYSA-N
grade
analytical standard
product line
VETRANAL®
shelf life
limited shelf life, expiry date on the label
technique(s)
HPLC: suitable
gas chromatography (GC): suitable
application(s)
forensics and toxicology
pharmaceutical (small molecule)
veterinary
format
neat
storage temp.
2-8°C
Quality Level
Gene Information
human ... PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
Application
依托考昔已被用作参考标准品，用于通过液相色谱-串联质谱-常压化学电离分析法（LC-APCI/MS/MS）检测人血浆中的依托考昔。
有关合适仪器技术的更多信息，请参考产品′s分析证书。如需进一步支持，请联系技术服务。
General description
依托考昔是一种非甾体类环加氧酶-2（COX-2）选择性抗炎药，主要用于骨关节炎和类风湿性关节炎患者的治疗。
Legal Information
VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 2 Dermal - Acute Tox. 4 Oral
存储类别
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
Rik J Lories
Expert opinion on drug metabolism & toxicology, 8(12), 1599-1608 (2012-11-07)
Nonsteroidal anti-inflammatory drugs (NSAIDs) are first-line therapies in the management of patients with ankylosing spondylitis. This chronic inflammatory skeletal disorder, a subtype of spondyloarthritis, is characterized by inflammatory back pain and affects young adults causing important suffering and disability. Long-term
Rachel Clarke et al.
The Cochrane database of systematic reviews, (2)(2), CD004309-CD004309 (2009-04-17)
Etoricoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor prescribed for the relief of chronic pain in osteoarthritis and rheumatoid arthritis, and acute pain. The drug is believed to be associated with fewer upper gastrointestinal adverse effects than conventional non-steroidal anti-inflammatory drugs
Eugene R Viscusi et al.
Current medical research and opinion, 28(8), 1323-1335 (2012-06-29)
To evaluate the effects of two different doses of etoricoxib delivered perioperatively compared with placebo and standard pain management on pain at rest, pain with mobilization, and use of additional morphine/opioids postoperatively. In this double-blind, placebo-controlled, randomized clinical trial, we
Paola Patrignani et al.
Expert opinion on pharmacotherapy, 4(2), 265-284 (2003-02-04)
The development of COX2 inhibitors with improved biochemical selectivity (such as etoricoxib and valdecoxib) over that of commercially available coxibs has been driven by the potential advantage of safety using higher coxib doses for increased efficacy. Etoricoxib has been approved
Rachel Clarke et al.
The Cochrane database of systematic reviews, 4(4), CD004309-CD004309 (2012-04-20)
Etoricoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor licensed for the relief of chronic pain in osteoarthritis and rheumatoid arthritis, and acute pain in some jurisdictions. This class of drugs is believed to be associated with fewer upper gastrointestinal adverse effects
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持